News
Insiders Buying Outlook Therapeutics And 2 Other Stocks
1 Apr 24
Long Ideas, News, Small Cap, Insider Trades, Pre-Market Outlook, Markets, Trading Ideas
BTIG Upgrades Outlook Therapeutics to Buy, Announces $50 Price Target
27 Mar 24
News, Upgrades, Price Target, Analyst Ratings
HC Wainwright & Co. Maintains Buy on Outlook Therapeutics, Adjusts Price Target To $30 (reverse stock split 1:20)
25 Mar 24
News, Price Target, Analyst Ratings
Gold Moves Lower; Lululemon Shares Plummet
22 Mar 24
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets, Trading Ideas
Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day Session
22 Mar 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
12 Health Care Stocks Moving In Friday's Intraday Session
22 Mar 24
Movers
Dow Dips 200 Points; Nike Shares Fall After Q3 Results
22 Mar 24
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets, Trading Ideas
Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Higher On Friday?
22 Mar 24
Biotech, News, Health Care, Movers, Trading Ideas, General
12 Health Care Stocks Moving In Friday's Pre-Market Session
22 Mar 24
Movers
Market-Moving News for March 22nd
22 Mar 24
Movers, Trading Ideas
On 21 March 2024, EU's CHMP Adopted A Positive Opinion, Recommending The Granting Of A Marketing Authorization For Outlook Therapeutics' Lytenava, Intended For Treatment Of Neovascular Age-related Macular Degeneration
22 Mar 24
News, FDA
Over $1.7M Bet On Globalstar? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
12 Mar 24
Long Ideas, News, Penny Stocks, Small Cap, Insider Trades, Pre-Market Outlook, Markets, Trading Ideas
12 Health Care Stocks Moving In Thursday's After-Market Session
22 Feb 24
Movers
Chardan Capital Upgrades Outlook Therapeutics to Buy, Announces $3 Price Target
15 Feb 24
News, Upgrades, Price Target, Analyst Ratings
Outlook Therapeutics Provides Corporate Update; Formal Review Process For ONS-5010 MAA By EMA Committee For Medicinal Products For Human Use Is Underway With Decision Date In H1 2024; Explores Expanded Relationship With Cencora
14 Feb 24
Biotech, News, General
Outlook Therapeutics Q1 2024 GAAP EPS $(0.04) Beats $(0.05) Estimate
14 Feb 24
Earnings, Earnings Beats, News
Outlook Therapeutics Doses Subject For NORSE EIGHT Clinical Trial
31 Jan 24
Biotech, News, General
Guggenheim Upgrades Outlook Therapeutics to Buy, Announces $2 Price Target
25 Jan 24
News, Upgrades, Price Target, Analyst Ratings
Brookline Capital Upgrades Outlook Therapeutics to Buy, Announces $1.57 Price Target
25 Jan 24
News, Upgrades, Price Target, Analyst Ratings
12 Health Care Stocks Moving In Tuesday's Intraday Session
23 Jan 24
Movers
Press releases
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million
15 Apr 24
News, Financing, Press Releases
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
22 Mar 24
Health Care, Press Releases, General
Thinking about buying stock in Mind Medicine, Ocean Biomedical, Archer Aviation, Outlook Therapeutics, or Cardiff Oncology?
15 Mar 24
Opinion, Press Releases
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update
14 Feb 24
Earnings, Press Releases
Outlook Therapeutics® Doses First Subject in NORSE EIGHT
31 Jan 24
Health Care, Press Releases
Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010
23 Jan 24
Press Releases